載入中
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
前收盤價
US$3.99
+US$0.41 · +11.45%
盤中時間採用ET。市場資料可能有所延遲。
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
日內區間
目前US$3.99
52週區間
目前US$3.99
盤中時間採用ET。市場資料可能有所延遲。
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
日內區間
目前US$3.99
52週區間
目前US$3.99
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 463.2萬 USD | 298.3萬 USD | — | — | — |
| 銷貨成本 | 732.1萬 USD | — | — | — | — |
| 毛利 | −268.9萬 USD | 298.3萬 USD | — | — | — |
| 研究與開發 | 1.61億 USD | 1.55億 USD | 1.48億 USD | 8672.5萬 USD | 7055萬 USD |
| 銷售、一般及管理費用 | 5234.6萬 USD | 5016.1萬 USD | 4338.7萬 USD | 2981.9萬 USD | 1392.4萬 USD |
| 營業費用 | 2.06億 USD | 2.05億 USD | 2.05億 USD | 1.17億 USD | 8447.4萬 USD |
| 利息收入 | 414.9萬 USD | 352.2萬 USD | — | — | — |
| 折舊和攤銷 | 538.4萬 USD | 612.8萬 USD | 465.3萬 USD | 222.4萬 USD | 56.8萬 USD |
| 營業利益 | −2.08億 USD | −2.02億 USD | −2.05億 USD | −1.17億 USD | −8447.4萬 USD |
| 淨利 | −2.01億 USD | −1.96億 USD | −1.98億 USD | −1.22億 USD | −1.65億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$7.50
上漲空間 87.97%| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2018年3月22日 | US$0.006Quarterly | — | 2018年3月29日 |
除息 2018年3月22日
US$0.006
Quarterly
支付日 2018年3月29日
報告持有此股票曝險的交易所交易基金。
ARK Genomic Revolution ETFARKG2766.49萬1.35%15.57億 USD0.75%US$51.30+4.08%
State Street SPDR S&P Biotech ETFXBI1312.8萬0.13%98.74億 USD0.35%US$153.77+3.00%
Vanguard Morningstar Total Stock Market ETFVTI1120.24萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM886.95萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF473.86萬0.00%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO272.74萬0.02%139.17億 USD0.24%US$356.78+0.94%
iShares Biotechnology ETFIBB263.21萬0.03%108.2億 USD0.44%US$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA226.66萬0.01%218.24億 USD0.03%US$32.79+0.40%ARK Genomic Revolution ETFARKGState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
